TOMI Environmental Solutions Secures Two New Purchase Agreements with Leading Pharmaceutical Companies
TOMI Environmental Solutions (NASDAQ: TOMZ) announced two new purchase agreements with leading pharmaceutical companies. The first agreement involves a SteraMist Environment System and validation services for a major private pharmaceutical company in Mexico, marking an expansion of TOMI's global operations. The second agreement includes the sale of a SteraMist Hybrid System to BeSpoke Pharmaceuticals, a 503B product manufacturer in Nevada, valued at over $200,000. These deals highlight TOMI's strategic growth and market reach in the Life Sciences sector, underscoring their innovation and potential for long-term growth.
- Secured two significant purchase agreements in the Life Sciences sector.
- Expanded global footprint with a major pharmaceutical company's facility in Mexico.
- Sold a SteraMist Hybrid System to BeSpoke Pharmaceuticals, valued at over $200,000.
- Strengthened relationships with leading pharmaceutical companies.
- Demonstrated ability to scale and support international partners.
- Highlighted potential for long-term growth within the pharmaceutical industry.
- Emphasized innovative solutions and expanding market reach.
- No concrete revenue figures or financial impact details provided.
- Potential risks of over-reliance on a few significant deals for growth.
- No information on overall profitability or cost implications of these agreements.
- details on the terms of the purchase agreements.
Insights
TOMI Environmental Solutions' recent announcement of securing new purchase agreements with leading pharmaceutical companies is noteworthy for various reasons.
Revenue Impact: The agreements mentioned, especially the over
Market Expansion: Expanding their footprint in Mexico and continuing partnerships in the U.S. signify strategic growth and an ability to serve global markets. Increased geographic diversity reduces reliance on any single market and can lead to more stable long-term revenue streams.
Partnerships: The emphasis on collaboration with experienced partners like Indigo Pharmaceutical and other consultants boosts confidence in TOMI's market strategy. Partnerships can provide networks and expertise that help in penetrating new markets more efficiently.
From a retail investor perspective, these developments are positive indicators for TOMI's financial health and growth prospects in the short to medium term. However, investors should keep an eye on how these agreements evolve into sustained revenue growth and whether TOMI can maintain this trajectory.
Industry Position: TOMI's technology, specifically the Binary Ionization Technology (BIT) and its application through the SteraMist brand, addresses critical needs in the life sciences and pharmaceutical sectors, particularly in ensuring sterile environments. This niche has become more critical post-pandemic, emphasizing environments free from pathogens and contaminants.
Competitive Edge: The technology’s backing from the Defense Advanced Research Projects Agency (DARPA) adds a layer of credibility and showcases its innovative edge. This could be seen as a unique selling point that differentiates TOMI from competitors in the disinfection space.
Trend Alignment: The agreements underscore a broader trend in the pharmaceutical industry towards higher safety and more stringent contamination control, driven by regulatory requirements and consumer expectations. TOMI seems well-aligned with these trends, positioning itself as a key player in an evolving market.
Overall, the expanding market reach and alignment with industry trends indicate a promising outlook. Retail investors should consider these factors as part of a bigger picture of industry growth and technological adoption.
FREDERICK, Md., June 10, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, is pleased to announce two recent sales in the Life Sciences sector, underscoring the Company’s successful strategic expansion in the sector and growth potential.
The first purchase agreement, signed with one of the largest private pharmaceutical companies in the world, includes the acquisition of a SteraMist Environment System and TOMI validation services for the client’s vivarium facility in Mexico. This landmark contract strengthens TOMI’s long-standing relationship with the company in the United States and expands TOMI’s footprint in its global operations, highlighting the Company’s ability to scale and support international partners.
The second purchase agreement arises from the Company’s collaboration with a trusted partner with decades of experience in big pharma. This partnership facilitated the sale of the first Hybrid System to Indigo Pharmaceutical, Inc. as announced in September 2023. Continuing this momentum, the partner has now successfully sold another SteraMist Hybrid System to BeSpoke Pharmaceuticals, a Nevada-based manufacturer targeting 503B products. This advanced turnkey custom installation, valued at over
“These two wins represent the significant progress TOMI is making in expanding our reach and capabilities within the pharmaceutical industry, reinforcing the Company’s potential for long-term growth,” said Elissa J. (E.J.) Shane, Chief Operating Officer of TOMI. “Building and expanding our presence within these large companies is a strategic priority for the Company. With the broad array of product offerings we provide, we are confident in our ability to meet and exceed our customers' needs. Furthermore, the partnerships we have cultivated, including consultants, designers, and contractors for new facilities around the world, are critical to this expansion. These relationships and our business development strategies now firmly position us for future success. We look forward to continuing to leverage our superior technology and industry relationships to drive increased market penetration in the rapidly evolving Life Sciences sector.”
TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.
TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.
TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.
For additional information, please visit https://www.steramist.com/ or contact us at info@tomimist.com.
Forward-Looking Statements
This press release contain forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to cost reduction measures and compensation changes; anticipated launch of new products; expected growth in sales pipeline and market demand; revenue opportunities of CES products and brand recognition of our products. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Roz Christian
IMS Investor Relations
FAQ
What are the new purchase agreements secured by TOMI Environmental Solutions?
How will the new agreements affect TOMI Environmental Solutions' market reach?
What is the value of the agreement with BeSpoke Pharmaceuticals?
What technology is TOMI Environmental Solutions known for?
What is the significance of TOMI's new purchase agreements in the Life Sciences sector?
